About: Potential Fast COVID-19 Containment With Trehalose

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Potential Fast COVID-19 Containment With Trehalose Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Potential Fast COVID-19 Containment With Trehalose
Creator	Shimada, K Borges, V Gomez, A Martinon, D
Source	Medline; PMC
abstract	Countries worldwide have confirmed a staggering number of COVID-19 cases, and it is now clear that no country is immune to the SARS-CoV-2 infection. Resource-poor countries with weaker health systems are struggling with epidemics of their own and are now in a more uncertain situation with this rapidly spreading infection. Frontline healthcare workers are succumbing to the infection in their efforts to save lives. There is an urgency to develop treatments for COVID-19, yet there is limited clinical data on the efficacy of potential drug treatments. Countries worldwide implemented a stay-at-home order to “flatten the curve” and relieve the pressure on the health system, but it is uncertain how this will unfold after the economy reopens. Trehalose, a natural glucose disaccharide, is known to impair viral function through the autophagy system. Here, we propose trehalose as a potential preventative treatment for SARS-CoV-2 infection and transmission.
has issue date	2020-07-07(xsd:dateTime)
bibo:doi	10.3389/fimmu.2020.01623
bibo:pmid	32733488
has license	cc-by
sha1sum (hex)	fda2c23851daffe89c605d6f1f005890e5cf15da
schema:url	https://doi.org/10.3389/fimmu.2020.01623
resource representing a document's title	Potential Fast COVID-19 Containment With Trehalose
has PubMed Central identifier	PMC7358456
has PubMed identifier	32733488
schema:publication	Front Immunol
resource representing a document's body	covid:fda2c23851daffe89c605d6f1f005890e5cf15da#body_text
is schema:about of	named entity 'function' named entity 'infection' named entity 'health system' named entity 'LIMITED' named entity 'HERE' named entity 'COVID-19' named entity 'There' named entity 'save' named entity 'treatments' named entity 'develop' named entity 'clear' named entity 'curve' named entity 'glucose' named entity 'disaccharide' named entity 'SARS-CoV-2' named entity 'infection' named entity 'autophagy' named entity 'viral replication' named entity 'adenovirus' named entity 'COVID' named entity 'SARS-CoV-2' named entity 'randomized controlled trials' named entity 'Phase 2' named entity 'Remdesivir' named entity 'trehalose' named entity 'hydroxychloroquine' named entity 'HIV protease inhibitor' named entity 'clinical research trials' named entity 'infection' named entity 'intensive care' named entity 'herd immunity' named entity 'non-specific' named entity 'clinical trial' named entity 'oseltamivir' named entity 'trehalose' named entity 'fructose' named entity 'vacuole' named entity 'immunotherapies' named entity 'macaques' named entity 'inflammatory cytokines' named entity 'antiviral drug' named entity 'COVID' named entity 'coronaviruses' named entity 'glucose' named entity 'TFEB' named entity 'trehalose' named entity 'algae' named entity 'autophagy' named entity 'autophagy' named entity 'trehalose' named entity 'autophagy' named entity 'membrane vesicles' named entity 'trehalose' named entity 'viral replication' named entity 'ritonavir' named entity 'National Institute of Allergy and Infectious Disease' named entity 'COVID' named entity 'trehalose' named entity 'trehalose' named entity 'herd immunity' named entity '85%' named entity 'autophagy' named entity 'platelet activation' named entity 'glucose' named entity 'HIV' named entity 'asymptomatic' named entity 'glucose tolerance' named entity 'mice' named entity 'trehalose' named entity 'endosomal' named entity 'chronic diseases' named entity 'trehalose' named entity 'mitophagy' named entity 'angiotensin-converting enzyme 2' named entity 'COVID-19' named entity 'lysosome' named entity 'human cytomegalovirus' named entity 'vaccine'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software